Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

JediGreen May. 22 at 5:52 AM

$BCTX Scroll down to poster publications 2026 and you’ll find all the good stuff on the link below ⬇️

0 · Reply

JediGreen May. 22 at 5:45 AM

$BCTX BriaCell Publications | Cancer Research & Findings https://briacell.com/scientific-publications/

0 · Reply

rade4481 May. 22 at 3:57 AM

$BCTX https://www.asco.org/abstracts-presentations/261300

0 · Reply

JediGreen May. 22 at 3:53 AM

$BCTX is it doing better then current standard of care?

1 · Reply

Fvalstounge May. 22 at 1:01 AM

$BCTX P3 enrollment updates, AACR vs. ASCO: Screened: 235 to 251 (+16) Randomized: 169 to 173 (+4) Treated: 129 to 147 (+18) Once they sign consent to treat and get randomized, they "count". With 50 being randomized to the monotherapy, still just 61/62 randomized to investigative and control arms. This pace doesn't support an interim review happening anytime soon.

3 · Reply

JediGreen May. 22 at 12:43 AM

$BCTX Did it really show anything on OS or do we have to wait until June?

0 · Reply

JediGreen May. 22 at 12:34 AM

$BCTX How dose it look. Don’t have time to look at it now.

0 · Reply

BHWinehouse May. 21 at 11:05 PM

$BCTX To me this is very encouraging, no red flags, just good positive info including evidence that a subset of patients may experience unusually durable survival. 251 screened 173 randomized 147 treated I couldn't be more bullish at this point, hang in there, it's going to be a minute for the ph3 unblinding. GLTA

2 · Reply

superguild May. 21 at 10:12 PM

$BCTX i pr$BCTX i predict a rug pull tomorrow. Seems to be the pattern

1 · Reply

2maligators May. 21 at 9:43 PM

$BCTX so much for just getting back to $4🫩

1 · Reply

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 7 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 7 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 8 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 8 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 8 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 9 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 14 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 15 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 15 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 24 days ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 4 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 4 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 7 weeks ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 2 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 4 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 4 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:08:02.000Z - 4 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 4 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

2026-01-13T12:35:49.000Z - 4 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Tue, 13 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 5 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T12:41:29.000Z - 5 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

Dec 10, 2025, 7:30 AM EST - 5 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T12:35:35.000Z - 5 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

Dec 9, 2025, 7:30 AM EST - 5 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:36:29.000Z - 6 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

Dec 2, 2025, 7:30 AM EST - 6 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 6 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T12:40:35.000Z - 6 months ago

BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics

Nov 20, 2025, 7:30 AM EST - 6 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 6 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

2025-11-07T12:41:48.000Z - 6 months ago

BriaCell presents anti-cancer activity of Bria-OTS at SITC 2025

Nov 7, 2025, 7:30 AM EST - 6 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-22T11:37:13.000Z - 7 months ago

BriaCell says DSMB recommends continuation of Phase 3 Bria-IMT study

Oct 21, 2025, 7:50 AM EDT - 7 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 8 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 9 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 10 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 11 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 11 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 11 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 11 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

JediGreen May. 22 at 5:52 AM

$BCTX Scroll down to poster publications 2026 and you’ll find all the good stuff on the link below ⬇️

0 · Reply

JediGreen May. 22 at 5:45 AM

$BCTX BriaCell Publications | Cancer Research & Findings https://briacell.com/scientific-publications/

0 · Reply

rade4481 May. 22 at 3:57 AM

$BCTX https://www.asco.org/abstracts-presentations/261300

0 · Reply

JediGreen May. 22 at 3:53 AM

$BCTX is it doing better then current standard of care?

1 · Reply

Fvalstounge May. 22 at 1:01 AM

3 · Reply

JediGreen May. 22 at 12:43 AM

$BCTX Did it really show anything on OS or do we have to wait until June?

0 · Reply

JediGreen May. 22 at 12:34 AM

$BCTX How dose it look. Don’t have time to look at it now.

0 · Reply

BHWinehouse May. 21 at 11:05 PM

2 · Reply

superguild May. 21 at 10:12 PM

$BCTX i pr$BCTX i predict a rug pull tomorrow. Seems to be the pattern

1 · Reply

2maligators May. 21 at 9:43 PM

$BCTX so much for just getting back to $4🫩

1 · Reply

Kirubin May. 21 at 7:39 PM

$BCTX posters coming out today! 💀🐏🐏🐏🐏

0 · Reply

beachbroke May. 21 at 10:23 AM

$BCTX

0 · Reply

BHWinehouse May. 21 at 10:00 AM

$BCTX Posters will be released at 5 P.M. EST.....

2 · Reply

Ares77manoe May. 21 at 8:50 AM

$BCTX buy the rumor sell the news...be careful anyway.Trade dont hope.Will scale out some before symposium.

0 · Reply

JediGreen May. 21 at 3:58 AM

$BCTX BriaCell Announces Six Clinical Data Presentations at ASCO 2026 https://finance.yahoo.com/sectors/healthcare/articles/briacell-announces-six-clinical-data-113000237.html

0 · Reply

Goodstockday May. 21 at 12:26 AM

$BCTX My expectations are low for what we will get from the abstracts. It seems phase 3 is still blinded. Maybe, we get some interesting phase 2 data. Overall, I am not expecting the really good stuff until late this year.

1 · Reply

JediGreen May. 21 at 12:01 AM

$BCTX I have a feeling that’s why the took it down on Friday they probably getting ready for it to start moving up fast in my opinion. Data and bullish Baby.

1 · Reply

JediGreen May. 20 at 11:59 PM

$BCTX I have a feeling we could see phase 3 in 2 to 4 month tick tock. But tomorrow should be interesting when we start seeing the end of phase 2 data on OS I think that’s tomorrow. See how good the drug is doing and should give a big hint for upcoming phase 3 readout. Bullish Baby

0 · Reply

Orlandotrader May. 20 at 7:10 PM

$BCTX Thanks for the Friday Gift.

1 · Reply

Rohtan May. 20 at 5:38 PM

$BCTX it’s going to free fall again. Lol

2 · Reply

ZacksResearch May. 20 at 5:18 PM

$BCTX is expanding beyond breast cancer — and ovarian could be the next big opportunity 👀 BriaCell is advancing Bria-OVA+, a next-gen personalized, off-the-shelf immunotherapy for ovarian cancer using its Bria-OTS+™ platform. 🧬 Management highlighted encouraging Phase 2 metastatic breast cancer data 🔥 Preclinical Bria-BRES+ data showed activation of T cells, dendritic cells, and NK cells 🎯 Development work for Bria-OVA+ is already underway after licensing ovarian cancer cell lines from ATCC See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38152&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38152

0 · Reply

rp6577 May. 20 at 4:33 PM

$BCTX shorties running for the door at the moment

1 · Reply

Market Cap	28.13M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	197,000
Avg Vol	206,678
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	54%
Beta	1.26
Analysts	Strong Buy
Price Target	$40.00